Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor

Inventiva IVA announced the results of a clinical thorough QT/QTc study demonstrating the safety of lanifibranor on cardiac electrical activity.
The assessment of lanifibranor on cardiac repolarization was conducted under FDA in Phase 1 double-blind clinical trial to be included in the marketing application package of lanifibranor for the treatment of NASH.
The trial enrolled 217 healthy subjects who were randomized into four arms.
The primary electrocardiogram (ECG) endpoint was monitored during the first 24hrs and on the last day of treatment.
Lanifibranor administered at the anticipated maximal therapeutic dose of 1200mg/day and the supra-therapeutic dose of 2400mg/day had no impact on QT/QTc interval.
Lanifibranor was well tolerated at both dose levels.
Related: Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022.
Price Action: IVA shares closed at $13.61 on Monday.